The Role of Olmesartan Medoxomil in the Management of Hypertension

Overview

Journal Drugs

Specialty Pharmacology

Date 2004 Nov 26

PMID 15563246

Citations 5

Authors

Thomas Unger

Gordon T McInnes

Joel M Neutel

Michael Bohm

Affiliations

Soon will be listed here.

Abstract

Intensive blood pressure control is a desirable and obtainable goal in patients with hypertension, according to the most recent treatment guidelines from Europe and the US. Achieving target blood pressure depends on the efficacy of antihypertensive treatment and patient compliance. Olmesartan medoxomil, a non-peptidergic angiotensin AT1 receptor antagonist, has been shown to be effective and well tolerated. Continuation of initial treatment is higher with AT1 receptor antagonists than for any other class of antihypertensive drugs. Olmesartan medoxomil may also have end-organ protective effects that provide additional clinical benefit. Optimal blood pressure control may be achieved faster if initial treatment contains the most efficacious and well tolerated antihypertensive drug or drugs. The ongoing European study, known as OLMEBEST (Efficacy and safety of OLMEsartan: reduction of Blood pressure in the treatment of patients suffering from mild to moderate ESsenTial hypertension), will provide important information on the use of olmesartan medoxomil as an initial treatment for hypertension.

Citing Articles

ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.

Presta V, Figliuzzi I, Citoni B, Gallo G, Battistoni A, Tocci G High Blood Press Cardiovasc Prev. 2021; 28(3):255-262.

PMID: 33710599 PMC: 7953181. DOI: 10.1007/s40292-021-00443-z.

Angiotensin II receptor antagonists (AT-blockers, ARBs, sartans): similarities and differences.

van Zwieten P Neth Heart J. 2015; 14(11):381-387.

PMID: 25696573 PMC: 2557311.

Effect of probenecid on pharmacokinetics and tolerability of olmesartan in healthy chinese volunteers.

Li K, Qiu Y, Jiang Y, Luo C, Lin X, Wang J Curr Ther Res Clin Exp. 2014; 76:7-10.

PMID: 25067982 PMC: 3994918. DOI: 10.1016/j.curtheres.2013.11.004.

Olmesartan medoxomil for the treatment of hypertension in children and adolescents.

Tocci G, Volpe M Vasc Health Risk Manag. 2011; 7:177-81.

PMID: 21490943 PMC: 3072741. DOI: 10.2147/VHRM.S11672.

RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms.

Bari P, Rote A Chromatographia. 2009; 69(11-12):1469-1472.

PMID: 19568313 PMC: 2701495. DOI: 10.1365/s10337-009-1094-z.

References

Parving H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345(12):870-8. DOI: 10.1056/NEJMoa011489. View

Kannel W . Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995; 18(3):181-96. DOI: 10.1291/hypres.18.181. View

Ohki R, Yamamoto K, Ueno S, Mano H, Ikeda U, Shimada K . Effects of olmesartan, an angiotensin II receptor blocker, on mechanically-modulated genes in cardiac myocytes. Cardiovasc Drugs Ther. 2003; 17(3):231-6. DOI: 10.1023/a:1026120123461. View

Oparil S, Williams D, Chrysant S, Marbury T, Neutel J . Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001; 3(5):283-91, 318. PMC: 8101821. DOI: 10.1111/j.1524-6175.2001.01136.x. View

Chrysant S, Weber M, Wang A, Hinman D . Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004; 17(3):252-9. DOI: 10.1016/j.amjhyper.2003.11.003. View

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B . The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003; 21(5):875-86. DOI: 10.1097/00004872-200305000-00011. View

Okin P, Devereux R, Jern S, Kjeldsen S, Julius S, Nieminen M . Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003; 108(6):684-90. DOI: 10.1161/01.CIR.0000083724.28630.C3. View

Koike H . New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001; 87(8A):33C-36C. DOI: 10.1016/s0002-9149(01)01540-5. View

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

10.

Bakris G, Williams M, Dworkin L, ELLIOTT W, Epstein M, Toto R . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36(3):646-61. DOI: 10.1053/ajkd.2000.16225. View

11.

Klag M, Whelton P, Randall B, Neaton J, Brancati F, Ford C . Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334(1):13-8. DOI: 10.1056/NEJM199601043340103. View

12.

. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21(6):1011-53. DOI: 10.1097/00004872-200306000-00001. View

13.

Franklin S, Jacobs M, Wong N, LItalien G, Lapuerta P . Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension. 2001; 37(3):869-74. DOI: 10.1161/01.hyp.37.3.869. View

14.

Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y . Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003; 14(5):1212-22. DOI: 10.1097/01.asn.0000062961.76776.c1. View

15.

Ball K, Williams P, Stumpe K . Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001; 19(1):S49-56. DOI: 10.1097/00004872-200106001-00007. View

16.

Puchler K, Laeis P, Stumpe K . Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl. 2001; 19(1):S41-8. DOI: 10.1097/00004872-200106001-00006. View

17.

Meissner I, Whisnant J, Sheps S, Schwartz G, OFallon W, Covalt J . Detection and control of high blood pressure in the community : Do we need a wake-up call?. Hypertension. 1999; 34(3):466-71. DOI: 10.1161/01.hyp.34.3.466. View

18.

Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H . Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol. 1995; 285(2):181-8. DOI: 10.1016/0014-2999(95)00401-6. View

19.

Hajjar I, Kotchen T . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290(2):199-206. DOI: 10.1001/jama.290.2.199. View

20.

Macmahon S . Antihypertensive drug treatment: the potential, expected and observed effects on vascular disease. J Hypertens Suppl. 1990; 8(7):S239-44. View